Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure

NCT ID: NCT01748240

Last Updated: 2019-06-04

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-03-31
• Study Completion Date: 2015-07-31

Brief Summary

Azacytidine (AZA) is the current standard of care for frontline patient treated with high-risk MDS and is clinically active in all type of MDS, however, 50% of the patients will never respond. Vorinostat is an orally available HDAC inhibitor with clinical activity in MDS and proven in vitro synergy with AZA. Patient treated upfront with a combination of this agents have shown more responses based on phase I/II data. In the present study, we will use the combination of these two drugs to try to create a synergetic effect and generate a response for patients who experienced treatment failure after AZA.

All eligible patients will be treated with Azacitidine and oral vorinostat for 6 cycles of 28 days. Study Design

Detailed Description

Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two times daily for 7 days as outlined in table 1.1. AZA will be administered SC at 75 mg/m2/day x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.

Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting on day 3.

Patients will receive 6 cycles unless progression is documented. Patients with a complete remission (CR), partial remission (PR), or hematological improvement (HI), will be treated until progression.

Conditions

Myelodysplastic Syndrome

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Azacitidine and oral vorinostat

Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two times daily for 7 days. AZA will be administered SC at 75 mg/m2/day x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.

Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting on day 3.

Group Type: EXPERIMENTAL

Azacitidine and oral vorinostat

Intervention Type: DRUG

In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.

Interventions

Azacitidine and oral vorinostat

In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.

Intervention Type: DRUG

Other Intervention Names

Suberoylanilide Hydroxamic acid (Vorinostat); Azacitidine (Vidaza)

Eligibility Criteria

Inclusion Criteria

• Myelodysplastic syndrome (WHO and FAB classified) including: RA, RARS, RCMD, RCMD-RS RAEB , RAEB-t and CMML with WBC < 13000/mm3)
• IPSS score 1.5 or higher (IPSS intermediate-2 and high risk categories) at the beginning of azacitidine,
• Absence of response (CR, PR, marrow CR or HI according to IWG 2006) after a minimum of 6 cycles of azacitidine single agent at 75 mg/m²/d for 7 days per cycle. Patients with a previous dose reduction of AZA may be eligible if the maximum tolerated dose was equal to or above 350mg/m2/cycle (i.e. 50 mg/m²/d for 7 days or 75mg/m2/d for 5 days).
• Age more or egal to 18 years
• ECOG performance status ≤ 2 (cf. appendix 2);
• Patient must have adequate organ function as indicated by the following laboratory values

Renal Serum creatinine or calculated creatinine clearancea < 2 mg/dl OR ≥ 60 mL/min for patients with creatinine levels > 1.5 X institutional ULN Hepatic

Serum total bilirubin ≤ 2.5 X ULN OR direct bilirubin ≤ ULN for patients with total bilirubin levels ≥ 2 mg/dL.

AST (SGOT) and ALT (SGPT) ≤ 2.5 times ULN Alkaline Phosphatase ≤ 5 X ULN If > 2.5 X ULN, then liver fraction should be ≤ 2.5 X ULN a Creatinine clearance should be calculated per institutional standard.

• Patient is known to not be refractory to platelet transfusions.
• Patient ineligible for allogeneic hematopoietic stem cell transplantation at the time of inclusion in the study
• Adherence to the study visit schedule;
• Women of childbearing potential must:

Agree to use effective contraception without interruption throughout the study and for a further 3 months after the end of treatment;

• Men must: Agree to not conceive during the treatment and to use effective contraception during the treatment period (including periods of dose reduction or temporary suspension) and for a further 3 months after the end of treatment if their partner is of childbearing potential.

Agree to learn about the procedures for preservation of sperm.

Exclusion Criteria

• Patient had prior treatment with an HDAC inhibitor (e.g., depsipeptide or NSC-630176, MS 275, LAQ-824, PXD-101, LBH589, MGCD0103, CRA024781, etc). Patients who have received compounds with HDAC inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not enroll in this study. Patients who have received such compounds for other indications, e.g. valproic acid for epilepsy, may enroll after a 30-day washout period.
• Severe infection or any other uncontrolled severe condition.
• Last dose of AZA was given more than 3 months before entering the trial.
• Patient already enrolled in another therapeutic trial of an investigational drug
• HIV infection or active hepatitis B or C.
• Patient has a known allergy or hypersensitivity to any component of vorinostat or azacitidine.
• Active cancer, or cancer during the year prior to trial entry other than basal cell carcinoma or carcinoma in situ of the cervix or breast.
• Less than 30 days since prior treatment with growth factors (EPO, G-CSF) or non-cytotoxic agents (including low-dose oral chemotherapy); in the event of prior treatment with cytotoxic or demethylating agents, an interval of 3 months is required;
• Patient is on any systemic steroids that have not been stabilized to the equivalent of ≤ 10 mg/day prednisone during the 4 weeks prior to the start of the study drugs.
• Patients with clinical evidence of CNS leukemia.
• Patient has a history of GI surgery or other procedures that might interfere with the absorption or swallowing of the study drugs.
• Women who are or could become pregnant, or who are currently breastfeeding
• Patient eligible for allotransplantation at the time of inclusion.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: collaborator

Groupe Francophone des Myelodysplasies

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Thomas Prebet, MD

Role: PRINCIPAL_INVESTIGATOR

Unité d'Hématologie-Institut Paoli Calmettes,Marseille

Pierre Fenaux, MD

Role: STUDY_DIRECTOR

Hôpital Saint Louis, hematology

Locations

CHU d'Angers

Angers, , France

CH Annecy

Annecy, , France

Hôpital Avignon

Avignon, , France

Centre hospitalier de la côte Basque

Bayonne, , France

Hôpital Avicenne

Bobigny, , France

CHU de Grenoble

Grenoble, , France

CH Le mans

Le Mans, , France

CH Lyon Sud

Lyon, , France

IPC-Unité d'Hématologie 3

Marseille, , France

CHU Nantes

Nantes, , France

Hôpital Archet1

Nice, , France

GHU Caremeau

Nîmes, , France

Hôpital Saint Louis

Paris, , France

Hopital Saint Louis - AP-HP, Hematology Dpt

Paris, , France

Hôpital Saint-Louis

Paris, , France

Hopital Cochin-Hematology

Paris, , France

Centre Hospitalier Joffre

Perpignan, , France

CHU de Haut-Lévèque

Pessac, , France

Centre Henri Becquerel

Rouen, , France

Hopital Purpan-Medecine interne

Toulouse, , France

Hôpital PURPAN, Service d'Hématologie Clinique

Toulouse, , France

CHU Bretonneau

Tours, , France

CH de Valence

Valence, , France

CHU Brabois

Vandœuvre-lès-Nancy, , France

Countries

France

Other Identifiers

GFM-Aza-Vor 2012-001401-25

Identifier Type: -

Identifier Source: org_study_id